In recent years, clinical research has demonstrated favorable therapeutic effects of TGP on disorders of the liver, cardiovascular, nervous, endocrine, and skeletal systems
Although these drugs have apparent good safety profiles and have been approved for use in treating type 2 diabetes it is still important to consider the fact that the detailed activities of DPP4/CD26 have not been established
This condition results in decreased mobility, higher medical costs, and increased mortality rates
As shown in Figure 7, since the filing of the main compound patents in 2006, Novo Nordisk has been applying for patents consistently over a period of 17 years, with heavier patenting activity in 2019, two years before Wegovy was approved
Prog Nucleic Acid Res Mol Biol
Benefits of GLP-1 treatment